Samsung Biologics on Oct. 21 posted in a regulatory filing consolidated revenue of 1.49 trillion won ($1.12 billion) for the quarter ended September, up 18.5 percent from a year earlier, driven by full-capacity operations at Plants 1 through 4, the ramp-up of Plant 5 and the first sales from its Rockville, Maryland, facility. Operating profit rose 1 percent to 640.1 billion won.
The company raised its 2026 revenue growth target to 20 percent from a range of 15 to 20 percent, pointing to annual sales of about 5.47 trillion won. Nine-month revenue reached 4.07 trillion won, up 24.4 percent from a year earlier.
Copyright ⓒ Aju Press All rights reserved.
